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Abstract
Introduction There are robust associations between use of anticholinergic medicines and adverse effects in older people. 
However, the nature of these associations for older people living with frailty is yet to be established.
Objectives The aims were to identify and investigate associations between anticholinergics and adverse outcomes in older 
people living with frailty and to investigate whether exposure is associated with greater risks according to frailty status.
Methods MEDLINE, CINAHL, EMBASE, Cochrane Database of Systematic Reviews, Web of Science and PsycINFO 
were searched to 1 August 2019. Observational studies reporting associations between anticholinergics and outcomes in 
older adults (average age ≥ 65 years) that reported frailty using validated measures were included. Primary outcomes were 
physical impairment, cognitive dysfunction, and change in frailty status. Risk of bias was evaluated using the Cochrane Risk 
of Bias In Non-randomised Studies of Interventions (ROBINS-I) tool. Meta-analysis was undertaken where appropriate.
Results Thirteen studies (21,516 participants) were included (ten community, one residential aged-care facility and two 
hospital studies). Observed associations included reduced ability for chair standing, slower gait speeds, poorer physical 
performance, increased risk of falls and mortality. Conflicting results were reported for grip strength, timed up and go test, 
cognition and activities of daily living. No associations were observed for transitions between frailty states, psychological 
wellbeing or benzodiazepine-related adverse reactions. There was no clear evidence of differences in risks according to 
frailty status.
Conclusions Anticholinergics are associated with adverse outcomes in older people living with frailty; however, the literature 
has significant methodological limitations. There is insufficient evidence to suggest greater risks based on frailty, and there 
is an urgent need to evaluate this further in well-designed studies stratifying by frailty.
 * David Mehdizadeh 
 d.mehdizadeh@student.bradford.ac.uk
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1 Introduction
Frailty is a condition characterised by loss of biological 
reserves, failure of physiological mechanisms and vulner-
ability to adverse outcomes after relatively minor stressor 
events, such as prescription of a new medication [1]. Older 
people with frailty are especially vulnerable to experienc-
ing adverse drug reactions (ADRs), with available evidence 
suggesting this is due to age-related physiological changes 
impacting on pharmacokinetics and pharmacodynamics [2]. 
The identification and stratification of older people living 
with frailty is therefore becoming increasingly important for 
medicines optimisation, with prescribing requiring constant 
vigilance, particularly when considering the safety of drug 
therapies [3]. The potential for medicines to become stress-
ors to older people with frailty can result in a sudden and 
disproportionate deterioration in physical, mental and social 
wellbeing [4]. Balancing safe and effective prescribing with 
minimising risks of medication-related harm in older people 
with frailty is a priority for the UK National Health Ser-
vice (NHS), which has recently adopted a population-based 
frailty stratification approach to medication reviews in pri-
mary care [5].
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Key Points 
Risks associated with anticholinergic burden among 
older people are well established; however, the nature of 
associations for those specifically living with frailty are 
not.
This review highlights that in older people with frailty, 
limited observational evidence indicates associations 
with reduced ability for chair standing, slower gait 
speeds, poorer physical performance, increased risk of 
falls and mortality.
Conflicting associations were reported for outcomes such 
as grip strength and cognition. No associations were 
observed for outcomes such as transitions between frailty 
states or change in psychological wellbeing.
Few studies within this review stratified by frailty grade, 
with no clear evidence of differential effects of anticho-
linergics by frailty.
There is a deficiency of studies investigating anticho-
linergic exposure with a frailty focus. Further research 
is needed to better inform the use of anticholinergics 
among older people living with frailty.
are particularly vulnerable to the adverse effects associated 
with anticholinergic burden [3].
To date, studies investigating anticholinergic burden have 
typically only focused on the older population as a whole, 
reporting varying degrees of association with adverse out-
comes [11–13]. However, the associations between anticho-
linergic medication exposure and adverse outcomes specifi-
cally in older people living with frailty remains unclear, and 
whether frailty severity has a risk-modifying role is yet to be 
established. Additionally, there is an absence of randomised 
controlled trial (RCT) evidence and long-term safety data 
from drug trials that could support further understanding of 
the safety of these medicines in frail patients, typically due 
to underrepresentation of older populations [19].
This systematic review aims to:
1. Identify and investigate the current evidence for the 
associations between anticholinergic medication expo-
sure and adverse health outcomes in older people living 
with frailty.
2. Investigate whether anticholinergic medication exposure 
is associated with greater risk of adverse outcomes for 
older people according to frailty status.
2  Methods
A protocol for this review was prospectively registered 
with PROSPERO https:// www. crd. york. ac. uk/ prosp 
ero/ displ ay_ record. php? Recor dID= 140046; reference 
CRD42019140046), and is reported using the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) recommendations (Appendix 1 of the supple-
mentary information file; see the Electronic Supplementary 
Material [ESM]) [20].
2.1  Inclusion Criteria
Prospective and retrospective cohort studies and case–con-
trol studies were eligible. The study population were older 
adults in primary, secondary or tertiary care. Studies were 
included if samples had an average age of 65 years and over, 
were exposed to anticholinergic medicines, and were liv-
ing with frailty. An average age of 65 years and over was 
selected for inclusion rather than a strict cut-off of 65 years, 
to expand the search more widely, acknowledging that this 
approach may also yield studies with participants younger 
than 65. Studies were not excluded entirely based on includ-
ing younger participants, providing the average age across 
the sample was 65 and over, representing an older sample 
as a whole.
Among the medications that may result in a deterio-
ration of older adults’ wellbeing, anticholinergic medi-
cations, specifically those which block acetylcholine by 
competitively binding to central and peripheral muscarinic 
receptors [6], have a particularly high rate of ADRs among 
older adults with advancing frailty [1, 7]. These include 
delirium, blurred vision, dry mouth, dry eyes, dizziness, 
heart rhythm disturbance, constipation, urinary retention 
and orthostatic hypotension, which can be harmful and are 
commonly observed among older persons [8–10]. There 
is also robust evidence of cumulative adverse effects of 
multiple anticholinergic medicines [11–14], referred to as 
anticholinergic burden [15], found to be associated with 
adverse outcomes including physical impairment, falls, 
cognitive dysfunction and all-cause mortality [11–14]. 
Older people are more likely to be exposed to potent 
anticholinergic medicines, with the prevalence of such pre-
scribing increasing in this population [16]. This is despite 
the availability of criterion-based resources, such as the 
Beers and STOPP/START criteria, which focus on the list 
of anticholinergic medicines that should be avoided, or 
used with caution in certain clinical scenarios [17, 18]. 
There are concerns for older people living with frailty, who 
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The age of 65 was used as this typically defines older peo-
ple in general [21], and it is the age to typically define older 
people in clinical practice guidelines for pharmacotherapy 
[22]. Also, the age of 65 was selected with a view to focus-
ing on older people with frailty, rather than just older peo-
ple. A systematic review reporting the prevalence of frailty 
found that it increased steadily with age, but only around 
4% of 65- to 69-year-olds were considered to be living with 
frailty [23]. The landmark study by Fried and colleagues 
which developed the frailty phenotype model also limited 
data analysis to those aged 65 and over [24]. Therefore, it 
was decided that an average age of 65 and over was the most 
suitable lower threshold for inclusion, with the perspective 
that the prevalence of frailty in younger ages would be low.
2.1.1  Frailty
Studies were included if any validated frailty assessment 
measure was used and if the study population, on average, 
was frail according to at least one frailty measure. In stud-
ies stratifying frailty status using the phenotype model, 
pre-frailty was defined as the presence of one or two com-
ponents from the following five components: weakness, 
slow walking speed, exhaustion, low physical activity and 
unintentional weight loss. The presence of three or more of 
these components characterised frailty [24]. Where frailty 
was not explicitly identified, studies were included if they 
reported measures of the clinical features of frailty, defined 
by the phenotype model only [24]. Established thresholds 
for frailty measures were used; for example, > 0.8 m/s for 
walking speed (gait) [25], > 12 s to complete the timed up 
and go test (TUGT) [26] and a grip strength of < 20 kg 
(females) or < 30 kg (males) [24]. A broad definition of 
frailty was adopted for this review, which may contribute 
to the heterogeneity of the outcome measures; however, we 
understand this cannot be avoided, due to the various clas-
sifications of frailty.
2.1.2  Anticholinergic Exposure
Anticholinergic exposure was defined as either (1) any medi-
cation with antimuscarinic activity according to the refer-
ence list by Salahudeen et al. [12] or (2) anticholinergic 
burden, where any method of characterising anticholiner-
gic burden was specified by name, e.g. Drug Burden Index 
(DBI) [27]. Where there was uncertainty in confirming 
anticholinergic status, the review team came to a consen-
sus opinion based on pharmacological/medical expertise. If 
anticholinergic exposure was a dichotomised composite vari-
able including multiple drug types, this composite measure 
was included where at least 60% of the constituent drugs had 
anticholinergic properties.
2.2  Outcomes
The primary outcomes were physical impairment, cognitive 
dysfunction and a change in frailty status. Outcomes repre-
senting physical impairment included, but were not limited 
to, reduced grip strength, slower TUGT and chair stand tests, 
falls and any other outcome which could characterise such 
impairment. Outcomes representing cognitive dysfunction 
included, but were not limited to, lower Montreal Cognitive 
Assessment (MoCA) and Mini-Mental State Examination 
(MMSE) scores, for example. Any specific instrument was 
considered as an outcome measure of physical impairment, 
activities of daily living (ADL) and cognitive dysfunction.
Secondary outcomes were any other adverse outcome that 
could be associated with anticholinergic exposure. These 
included, but were not limited to, unplanned hospitalisa-
tion, institutionalisation in to care homes or nursing homes, 
mortality, change in quality of life and ADRs.
2.3  Information Sources
The following databases were searched from inception to 1st 
August 2019, using an inclusive search strategy developed 
with the support of experienced librarians at the University 
of Bradford: MEDLINE (EBSCO), CINAHL (EBSCO), 
EMBASE, the Cochrane Database of Systematic Reviews, 
Web of Science and PsycINFO (EBSCO). Search strategies 
for each database are available (Appendix 2 of the Supple-
mentary Information file; see the ESM). Search terms repre-
sented three main domains: elderly/frailty, anticholinergics 
and epidemiological filters domain.
2.4  Study Selection
Two reviewers (DM and MH, HZ, OT or IM) screened 
titles and abstracts of identified studies. Full texts were then 
retrieved to determine eligibility for inclusion (DM and 
MH, HZ, OT or IM). One reviewer (DM) screened 100% 
of studies at each stage, and the other reviewers screened 
25% each. A screening flowchart was developed to assist 
the reviewers at both stages (Appendix 3 of the Supplemen-
tary Information file; see the ESM). Disagreements were 
settled by consensus discussion with a third reviewer (AC 
or DP). The search strategy and study selection process had 
no language restrictions, and where eligible studies were 
in a language other than English, the lead author was con-
tacted to request an English version. If unavailable, it was 
translated using Google Translate [28] and the translation 
accuracy was assessed by a pharmacologist literate in both 
English and the language of the manuscript. Forward and 
backward citation analyses of the selected studies were per-
formed using Publish or Perish™ software [29] and Web of 
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Science. Studies identified by citation analysis were subject 
to the same independent study selection process.
2.5  Data Extraction
A standardised proforma was developed and piloted by two 
reviewers (DM and MH), and subsequent changes were 
made to improve the data extraction tool. Two reviewers 
(DM and MH, HZ, OT or IM) independently extracted 
data using the final standardised proforma for the outcome 
measures. One reviewer (DM) extracted data for 100% of 
the studies, with the independent extraction process being 
shared as equal as possible amongst the other reviewers. 
There was no principal summary measure prioritised for 
extraction, and measures included, but were not limited 
to, odds ratios (ORs), hazard ratios (HRs), incident rate 
ratios (IRRs), unstandardised and standardised correlation 
coefficients and measures of average and spread. Disagree-
ments were settled by consensus discussion with a third 
reviewer (AC or DP). Covariate-adjusted and unadjusted 
data were extracted; however, only covariate-adjusted 
data were prioritised for the meta-analysis and narrative 
synthesis, as they provide more reliable estimates of out-
come associations. Adjustment variables and models were 
recorded using the proforma, and where authors presented 
multiple adjusted results, the full model was prioritised for 
extraction. Two independent reviewers (DM and OT or DP) 
extracted data for the meta-analysis. Lead authors of stud-
ies were contacted where additional data were required.
2.6  Assessment of Risk of Bias
Two independent reviewers (DM and MH, HZ, OT or IM) 
assessed risk of bias using the Cochrane Risk of Bias In 
Non-randomised Studies of Interventions (ROBINS-I) tool 
[30]. One reviewer (DM) assessed risk of bias for 100% of 
the studies, and the independent review was shared as equal 
as possible amongst the reviewers. Disagreement in the qual-
ity assessment was resolved by consensus discussion with 
a third reviewer (AC or DP). A table summarising how an 
overall risk of bias judgement can be reached is available 
(Appendix 4 of the Supplementary Information file; see the 
ESM).
2.7  Synthesis of Results
2.7.1  Meta‑analysis
We identified studies where adjusted data could be appro-
priately synthesised for meta-analysis, and sample sizes 
and coefficients with 95% confidence intervals (CIs) were 
extracted, specifically for the outcome of interest. We 
synthesised data for meta-analysis using the Hedges-Olkin 
method, with a Fisher Z transformation of coefficients [31], 
and generated summary forest plots using MedCalc, version 
19.4.0 [32]. Statistical heterogeneity was assessed using the 
I2 statistic, to determine whether the summary coefficient 
from the fixed effects (I2 < 50%) or random effects (I2 ≥ 
50%) modelling should be adopted [33]. Estimates were 
included in the pooled analysis, where they were adjusted 
for a minimum of age and sex.
2.7.2  Narrative Synthesis
Data unsuitable for meta-analysis were summarised using a 
narrative synthesis, following guidance developed by Popay 
et al. [34].
3  Results
3.1  Literature Search
Details of the study selection are summarised in the 
PRISMA flowchart (Fig. 1). The search identified 17,589 
studies, of which seventy four were retrieved for full-text 
review. Of these, thirteen met the eligibility criteria and were 
included within this systematic review [35–47]. Reasons for 
excluding the sixty one studies are available (Appendix 5 of 
the Supplementary Information file; see the ESM). Back-
ward and forward citation analysis on 28th November 2019 
revealed 1000 studies (after removing duplicates), of which 
six were identified for full-text review; none of which met 
eligibility criteria.
Two studies reported multiple outcomes, in which one 
outcome (grip strength) was possible to synthesise within a 
meta-analysis [39, 45]. We attempted to contact authors of 
two studies for further data to ascertain eligibility, but this 
was without success; therefore, both were excluded [48, 49].
3.2  Study Characteristics
Four prospective cohort studies [35, 40, 41, 43], three 
retrospective cohort studies [37, 44, 46], four cross-sec-
tional studies [36, 38, 39, 42], one case–control study [47] 
and one study including both a cross-sectional and retro-
spective cohort design were included [45], with a total 
of 21,516 participants (Table 1). The prospective cohort 
studies had a mean follow-up of 2.4 years (range 9 months 
to 5 years) and a median sample size of 1257 (range 
204–12,405) [35, 40, 41, 43]. The retrospective cohort 
studies had a mean follow-up of 3.75 years (range 1–8 
years) and a mean sample size of 1183 (range 602–1793) 
[37, 44–46], and the case–control study had a sample size 
of 428, with a follow-up of 1 year [47]. Ten studies were 
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based in the community [36–39, 41–45, 47], one of which 
was in self-care retirement villages [39]. One study was 
based in a residential aged care facility [46], one study 
included older adults recruited based on attending a hos-
pital outpatient department [40], and one was based in 
a tertiary care inpatient hospital setting [35]. Four stud-
ies were conducted in Europe [38, 42–44], three in North 
America [36, 37, 40], four in Australia [35, 39, 41, 46], 
one in Malaysia [47] and one in Japan [45]. All studies 
were in the English language, except for one, which has an 
abstract published in English and the full-text in Japanese, 
which was translated [45].
3.3  Participant Characteristics
The mean participant age was 80.3 years (SD 3.73), reported 
in nine studies [35–39, 41, 42, 44, 46]. One study reported 
a median age of 87 years (range 86–88 years) in the cross-
sectional analyses [45]. Two studies did not report average 
Fig. 1  A PRISMA diagram 
reporting the identification 
of include studies. PRISMA 
Preferred Reporting Items for 
Systematic Reviews and Meta-
Analyses




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Associations Between Anticholinergics and Adverse Outcomes in Older People with Frailty
age, and instead one study reported 46.4% of participants 
were aged over 75 years [40] and another study reported 
67.7% were aged over 65 years (range 58–73) [43]. Across 
the included studies, 55.4% of participants were female 
(range 0–100%) [35–47].
3.4  Assessment of Frailty
Participants with pre-frailty/frailty were identified by study 
authors in six studies [35, 37, 40, 41, 43, 44], according to 
the phenotype model [24], Edmonton Frail Scale [50], the 
Strawbridge questionnaire [51] or 10-point frailty criteria 
[52]. Among these, the mean prevalence of frailty was 40.9% 
(range 3.7–100%). Pre-frailty was also reported in two stud-
ies, with 43.9% [37] and 45.9% [44] of their respective study 
samples deemed pre-frail. The remaining studies reported at 
least one frailty measure, but did not explicitly define frailty 
as per the previously mentioned frailty measures [36, 38, 
39, 42, 45–47]. These included gait speed (m/s), TUGT (s), 
chair stands tests (s) and grip strength (kg) (Table 1).
3.5  Identifying Anticholinergic Exposures
The DBI [27] and the Anticholinergic Cognitive Burden 
(ACB) scale [53] were used to characterise the exposure of 
anticholinergic drugs in nine studies [36–39, 41, 44–47]. 
Others included fall-risk–increasing drugs (FRIDs) [35], 
prescription of at least one anticholinergic drug [40], pre-
scription of at least one drug with demonstrated serum 
anticholinergic activity [42] or prescription with at least one 
potentially inappropriate medicine (PIM) that had anticho-
linergic properties [43] (Table 1).
3.6  Primary Outcomes: Physical Impairment
3.6.1  Grip Strength
Two cross-sectional studies investigated the association 
between a one-unit increase in DBI score and grip strength, 
and data were synthesised within a meta-analysis with a 
pooled sample size of 421. One study was conducted by 
Gnjidic et al., among older people living in self-care retire-
ment villages in Australia (n = 115) [39], and the other by 
Sato et al., among community-dwelling older people in 
Japan (n = 306) [45]. Sato et al. also reported 3-year follow-
up data; however, only cross-sectional data were extracted 
for meta-analysis. With an I2 value of 98.2%, a random 
effects model was selected to conduct the analysis. Results 
showed that a one-unit increase in DBI was not associated 
with weaker grip strength (kg) among older participants with 
frailty living in the community (pooled adjusted (adj.) coef-
ficient 0.48 [95% CI − 0.286 to 0.869]) (Appendix 6 of the 
Supplementary File; see the ESM) [39, 45].
There were mixed results among four community-based 
cross-sectional studies, which could not be included within 
the meta-analysis. Two demonstrated that anticholinergic 
exposure was associated with weaker grip strength. In a US 
study by Cao et al., which included female participants if 
they had difficulty in two or more functional domains (n 
= 932), exposure to anticholinergic medication was associ-
ated with increased odds for weaker grip strength (defined 
as < 18 kg strength in the dominant hand) (adj. OR 2.4 [95% 
CI 1.1–5.3]) [36], and in a study in Italy by Landi et al. (n 
= 364), exposure to anticholinergics was associated with a 
weaker grip strength compared to non-exposure (adj. mean 
28.88 (SE ± 1.05) vs 31.33 (SE ± 0.81), p = 0.05) [42]. 
In contrast, two studies observed no association between 
anticholinergic medication and weaker grip strength among 
older people deemed to be living with frailty. In a study in 
Finland by Gnjidic et al. (n = 700), anticholinergic expo-
sure (DBI > 0) was not associated with weaker grip strength 
(change in adj. coefficient − 0.98 [95% CI − 2.05 to 0.08]) 
[38], and in the 3-year follow-up data presented by Sato et al. 
(n = 176), a one-unit increase in DBI was also not associated 
with a weaker grip strength (change in adj. coefficient − 0.78 
[95% CI − 2.44 to 0.88]) (Table 2) [45].
3.6.2  Gait Speed, TUGT and Chair Stands Tests
In the US cross-sectional study by Cao et al. (n = 932) [36], 
a sub-group of 158 participants exposed to anticholinergic 
medicines as per the DBI were at increased odds of having a 
slower gait speed (< 0.64 m/s) (adj. OR 3.6 [95% 1.6–8.0]). 
In the study of community-dwelling older people in Finland 
(n = 700), Gnjidic et al. found that a DBI score > 0 was 
associated with reduced gait speed over a 10-m distance, 
with a change in adjusted coefficient of − 0.13 (95% CI 
− 0.19 to − 0.08) [38]. However, Landi et al.’s study of 
community-dwelling participants in Italy (n = 364) reported 
no difference in adjusted mean gait speed between those 
exposed and not-exposed to anticholinergics (0.47 [SE ± 
0.02] vs 0.49 [SE ± 0.01] [p = 0.70]) (Table 2) [42].
Gnjidic et  al. [38] reported an association between 
anticholinergic exposure (DBI score > 0) and poorer perfor-
mance of the TUGT (change in adj. coefficient 1.13 [95% CI 
1.07–1.19]). However, Sato et al. found no association between 
a one-unit increase in DBI score and poorer performance in 
the TUGT, reporting a change in adjusted coefficient of 0.53 
(95% CI − 2.46 to 3.52) in the cross-sectional data and 0.38 
(95% CI − 2.00 to 2.75) at the 3-year follow-up (Table 2) [45].
In the US study by Cao et al., participants exposed to 
anticholinergic medicines were at significantly increased 
odds of difficulty in chair stands (inability to stand up five 
times from a chair without using the arms) (adj. OR 4.2 
[95% CI 2.0–8.7]) [36]. Poorer performance in chair stands 
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was also observed by Gnjidic et al. in those exposed to a DBI 
score > 0, with a longer time needed to complete five chair 
stands in those exposed (change in adj. coefficient 1.11 [95% 
CI 1.05–1.16]) (Table 2) [38].
3.6.3  Falls
In a retrospective cohort study of older participants living 
with frailty in Australian residential aged care facilities (n 
= 602), Wilson et al. reported that anticholinergic medica-
tion exposure (DBI ≥ 1) was associated with a higher risk 
of falls (adj. IRR 1.90 [95% CI 1.30–2.78]), compared to no 
exposure (adj. IRR 1.61 [95% CI 1.17–2.23]) (Table 2) [46].
In a case–control study of community-dwelling older 
participants living with frailty in Malaysia (n = 428), no 
association between exposure to anticholinergics and falls 
was observed after adjustments for age, gender and the num-
ber of comorbidities, in addition to the following variables: 
reduced right grip strength (adj. OR 1.4 [95% CI 0.8–2.4]), 
reduced left grip strength (adj. OR 1.4 [95% CI 0.85–2.4]), 
TUGT ≥ 13.5(s) (adj. OR 1.3 [95% CI 0.76–2.1]) and 
functional reach ≤ 18 cm (adj. OR 1.2 [95% CI 0.7–2.1]) 
(Table 2) [47].
3.6.4  Other Outcomes Related to Physical Impairment
In the US cross-sectional study by Cao et al. (n = 932) [36], 
exposure to anticholinergic medicines was associated with 
increased odds of poor balance (inability to hold a full tan-
dem stand for 10 s) (adj. OR 4.9 [95% CI 2.0–12]), poor 
mobility (great difficulty in walking half a mile, walking 
across a small room, climbing ten steps, stooping, crouch-
ing or kneeling) (adj. OR 3.2 [95% CI 1.5–6.9]) and poor 
extremity function (great difficulty in using fingers to grasp 
or to handle, raising arms up over the head or lifting and 
carrying 10 lb) (adj. OR 2.7 [95% CI 1.3–5.4]) (Table 2).
Two cross-sectional studies reported associations between 
anticholinergic medication exposure and the Short Physi-
cal Performance Battery (SPPB) test [39, 42]. In a different 
study conducted by Gnjidic et al. involving community-
dwelling older adults in Australia living with frailty (n = 
115), a one-unit increase in the DBI score was associated 
with a reduced SPPB score, with a change in adjusted coef-
ficient of − 1.28 (95% CI − 2.53 to − 0.04) [39]. In the study 
conducted by Landi et al. with community-dwelling older 
participants in Italy (n = 364), non-users of anticholinergic 
drugs had an adjusted mean SPPB score of 6.90 (SE ± 0.19), 
compared to an adjusted mean score of 6.19 in users (SE ± 
0.25) (p = 0.05), suggesting a reduction in physical perfor-
mance in those exposed (Table 2) [42].
In the study by Sato et al. involving community-dwelling 
older participants in Japan, a one-unit increase in DBI was 
found not to be associated with impaired performance in a 
one-leg balance test (duration in seconds) and the number 
of repetition stands over 30 s test in cross-sectional data 
(change in adj. coefficient − 0.32 [95% CI − 4.57 to 3.93] 
and − 1.30 [95% CI − 2.79 to 0.20], respectively) and at 
3-year follow-up (change in adj. coefficient 1.89 [95% CI 
− 1.49 to 5.28] and 0.08 [95% CI − 1.77 to 1.93], respec-
tively) (Table 2) [45].
3.7  Primary Outcomes: Cognitive Dysfunction
Two cross-sectional studies reported an association between 
anticholinergic burden and cognitive dysfunction [36, 45]. 
Cao et al. observed that older women living in the com-
munity in the USA and exposed to anticholinergics (n = 
932) were at increased odds of impaired cognitive function 
(characterised by an MMSE score ≤ 26), with an adjusted 
OR of 2.4 (95% CI 1.1–5.1) [36]. Sato et al. observed that in 
older community-dwelling Japanese participants (n = 306), 
a one-unit increase in the DBI score was associated with a 
lower MMSE score cross-sectionally (change in adj. coef-
ficient − 1.50 [95% CI − 2.96 to − 0.03]) [45]. However, 
this association was not evident at 3-year follow-up (change 
in adj. coefficient − 0.21 [95% CI − 1.78 to 1.35]) (Table 2).
3.8  Primary Outcomes: Change in Frailty Status
In a prospective cohort study in Australia by Jamsen et al., 
1705 community-dwelling male participants were studied 
over 5 years, using the DBI as the measure of anticholinergic 
burden and the Fried criteria to measure frailty [41]. A one-
unit increase in DBI score was not associated with transi-
tions in frailty status: from pre-frailty to frailty (adj. HR 1.03 
[95% CI 0.76–1.40], n = 114); from pre-frailty to death (adj. 
HR 1.18 [95% CI 0.89–1.56], n = 200); from frailty to death 
(adj. HR 0.92 [95% CI 0.73–1.16], n = 108) [41]. There 
was also no evidence that increasing anticholinergic burden 
was associated with reverse transitions of frailty state: from 
pre-frailty to a fit state (adj. HR 0.90 [95% CI 0.59–1.36], 
n = 172); from frailty to pre-frailty (adj. HR 0.65 [95% CI 
0.33–1.27], n = 35) (Table 2).
In a prospective cohort study by Martinot et al. in Aus-
tralia, 12,405 community-dwelling participants were studied 
over a 3-year period, with associations between exposure to 
at least one PIM and frailty transitions investigated, using 
the Strawbridge questionnaire to characterise frailty [43]. In 
participants exposed to PIMs of an anticholinergic nature, 
there was no association with transitions from frailty to a fit 
state (adj. HR 0.84 [95% CI 0.64–1.09]). Specifically, there 
was also no association between the following anticholiner-
gic medicine groups and transitions from a frail to fit state: 
prescription of long-acting benzodiazepines (adj. HR 0.89 
[95% CI 0.70–1.14]); concomitant use of two or more ben-
zodiazepines (adj. HR 0.93 [95% CI 0.61–1.41]); prolonged 
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use of benzodiazepines (adj. HR 1.01 [95% CI 0.74–1.37]); 
the concomitant use of two or more antidepressants (adj. HR 
0.57 [95% CI 0.25–1.32]) (Table 2).
3.9  Secondary Outcomes
3.9.1  Activities of Daily Living
Four cross-sectional studies reported associations between 
anticholinergic exposure and outcomes relating to ADL, 
including Instrumental Activities of Daily Living (IADL) 
and Barthel Index scores [36, 38, 42, 45].
In the study by Cao et al. among community-dwelling 
participants in the USA (n = 932), exposure to anticholiner-
gic burden was associated with disability in ADL (adj. OR 
3.4 [95% CI 1.7–6.9]) [36]. Disability in ADL was catego-
rised in to three groups: mild (no more than some difficulty 
with at least one ADL), moderate (unable to do at least one 
ADL or a great difficulty in two or more ADL) and severe 
(unable to do at least two ADL or a great difficulty with three 
or more) (Table 3).
In the study by Gnjidic et al. of community-dwelling 
older people in Finland (n = 700), anticholinergic expo-
sure was associated with impaired functional status, with 
a change in adjusted IADL coefficient of − 0.61 (95% CI 
− 0.84 to − 0.39) and a change in Barthel Index adjusted 
coefficient of − 3.21 (95% CI − 4.68 to − 1.75) where, in 
both, a lower score indicated greater impairment of func-
tion (Table 3) [38].
In the study by Landi et al. among community-dwelling 
participants in Italy (n = 364), anticholinergic exposure 
was associated with greater impairment of functional status 
[42]. Function was measured using the Minimum Data Set 
for Home Care Assessment instrument (MDS-HC), where 
impairment was indicated by higher scores on scales for 
ADL and IADL that ranged from 0 to 7 [42]. Anticholin-
ergic exposure was associated with a higher adjusted mean 
score for ADL of 1.68 (SE ± 0.15) compared to an adjusted 
mean score of 1.23 (SE ± 0.12) for non-exposure (p = 0.03), 
and for IADL, an adjusted mean score of 3.47 (SE ± 0.14) 
compared to an adjusted mean score of 2.71 (SE ± 0.11) 
with non-exposure (p < 0.001) (Table 3).
In the study by Sato et al. involving community-dwelling 
older participants in Japan, a one-unit increase in DBI score 
was not associated with a change in ADL adjusted coef-
ficient at baseline (− 0.95 [95% CI − 4.91 to 3.01]), but a 
change in ADL adjusted coefficient at 3 years of − 6.31 (95% 
CI − 11.61 to − 1.01) [45]. For IADL, a one-unit increase 
in DBI was associated with a change in adjusted coefficient 
of − 0.63 at baseline (95% CI − 0.99 to − 0.27), but this was 
not maintained at 3 years, with no statistically significant 
change in IADL adjusted coefficient observed (− 0.34 [95% 
CI − 0.79 to 0.10]). The number of participants at follow-up 
was significantly fewer than at baseline, with a difference of 
130 participants (Table 3) [45].
3.9.2  Adverse Drug Reactions
In a US prospective cohort study by Hanlon et al., com-
munity-dwelling older participants living with frailty were 
followed up in an outpatient setting after a hospital stay (n = 
808), and the associations of commonly prescribed medica-
tions with ‘any ADRs’ and specifically ‘preventable ADRs’ 
were investigated [40]. Assessment of prescribing, monitor-
ing, dispensing and adherence errors were undertaken to 
determine ADR preventability, through clinical consensus. 
Among anticholinergic medications in the adjusted analyses, 
warfarin use was associated with ‘any ADRs’ (adj. HR 1.51 
[95% CI 1.22–1.87]). Warfarin use was also associated with 
‘preventable ADRs’ (adj. HR 1.50 [95% CI 1.08–2.11]). 
There was no association between benzodiazepines and ‘any 
ADRs’ (adj. HR 1.23 [95% CI 0.95–1.58]). Adjusted data for 
associations between benzodiazepine use and ‘preventable 
ADRs’ were unavailable (Table 3).
3.9.3  Psychological Functioning
In the study by Sato et al. involving community-dwelling 
older participants in Japan [45], psychological function-
ing was investigated in association with anticholinergic 
medication exposure, where psychological functioning was 
measured by the Philadelphia Geriatric Center Morale Scale 
[54]. Anticholinergic exposure was not associated with a 
change in psychological functioning at baseline (change in 
adj. coefficient − 0.72 [95% CI − 1.79 to 0.35]) or at 3-year 
follow-up (change in adj. coefficient − 1.00 [95% CI − 2.47 
to 0.48]) (Table 3).
3.9.4  Risk of Outcomes Stratified by Frailty Status
Three cohort studies reported the association between 
anticholinergic medication exposure and adverse health 
outcomes stratified by frailty status, separating participants 
into groups of non-frail/fit, pre-frail and frail [35, 37, 44].
In a prospective cohort study in Australia by Bennett et al., 
204 frail older participants within a tertiary hospital setting 
were studied over a 9-month period, investigating the associa-
tion between FRID exposure and physical impairment, falls, 
hospitalisation (after a fall) and institutionalisation (nursing 
home admission or rehabilitation hospital) (Tables 2 and  3) 
[35]. Frailty was measured by the Edmonton Frail Scale. 
Overall, exposure to at least one FRID was associated with 
falls (adj. OR 1.7 [95% CI 1.3–2.1]). Among those with frailty, 
FRIDs exposure was associated with an adjusted OR of 1.5 
[95% CI 1.1–1.9]) for falls, whereas among fit older people, 
the falls risk associated with FRID exposure was greater (adj. 
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OR 2.4 [95% CI 1.3–6.1]). Overall, exposure to one or more 
FRIDs was associated with 1.3 times the odds of functional 
decline (adj. OR 1.3 [95% CI 1.1–1.6]), defined as an increase 
in Katz ADL score by 2 points from admission after 2 months 
[55]. Among older people with frailty, FRID exposure was 
associated with 1.2 times the odds of functional decline (adj. 
OR 1.2 [95% CI 1.0–1.5]), but in fit older people, no associa-
tion was observed (adj. OR 1.4 [95% CI 0.9–2.0]) (Table 2). 
There was no association between FRID exposure and hos-
pitalisation overall (adj. OR 1.1 [95% CI 0.9–1.4]) or in sub-
populations defined by frailty status: in those who were fit 
(adj. OR 1.3 [95% CI 0.8–4.6]) and those with frailty (adj. 
OR 1.0 [95% CI 0.8–1.4]). FRID exposure was associated 
with increased odds of institutionalisation overall (adj. OR 1.3 
[95% CI 1.1–1.6]) and in those with frailty (adj. OR 1.3 [95% 
CI 1.0–1.6]), but not in fit older people (adj. OR 1.3 [95% CI 
0.8–2.1]) (Table 3).
In a retrospective cohort study by Cossette et al., 1793 older 
community-dwelling participants in Canada were studied over 
a 3-year period, investigating the change in coefficients for the 
Physical Component Summary (PCS) and Mental Component 
Summary (MCS) of the 36-item Short Form Survey (SF-36) 
questionnaire, for every one-unit change in ACB score (Table 2) 
[37]. Thirty-three per cent of the study population were taking 
at least one anticholinergic drug as per the ACB scale, with 
22% scoring a total ACB score of 1–2. Frailty was measured 
using the phenotype model, characterising participants in to 
two categories: fit or pre-frail/frail. Among fit older people, 
a one-unit increase in the ACB score was associated with a 
change in PCS adjusted coefficient of −0.30 (95% CI − 0.54 
to − 0.06). In the pre-frailty/frailty group, a one-unit increase in 
ACB was associated with a change in PCS adjusted coefficient 
of − 0.61 (95% CI − 0.88 to − 0.33). For the MCS outcome 
there was no statistically significant association with a one-
unit change in ACB score in the non-frail group, reporting a 
change in adjusted coefficient of 0.04 (95% CI − 0.16 to 0.24). 
In the frail/pre-frail group, this was associated with a change in 
adjusted coefficient of 0.30 (95% CI 0.04–0.57).
In a retrospective cohort study by Porter et al. of commu-
nity-dwelling older adults with cognitive impairment in the 
UK (n = 1154), the effect of PIMs on all-cause mortality 
was investigated, stratified by frailty status [44]. 17.7% (n 
= 204) were identified as fit, 45.9% (n = 530) were pre-frail 
and 36.4% (n = 420) were frail, as per the phenotype model. 
Exposure to one or more anticholinergic PIMs was not asso-
ciated with a difference in mortality overall (adj. HR 3.60 
[95% CI 0.40–31.99]). However, specifically in those with 
pre-frailty and frailty, exposure to anticholinergic PIMs was 
also not associated with increased mortality risk (adj. HR 
1.05 [95% CI 0.61 to 1.79] and adj. HR 1.23 [95% CI 0.76 
to 2.01], respectively). In those exposed to antipsychotics, 
there was no association with increased risk of mortality 
in fit older people (adj. HR 3.60 [95% CI 0.40–31.99]). In 
those with pre-frailty, antipsychotic prescription was associ-
ated with increased risk of mortality (adj. HR 2.89 [95% CI 
1.26–6.66]), and this risk was greater in those with frailty 
(adj. HR 3.34 [95% CI 1.37–8.12]). There was no associa-
tion between benzodiazepine prescription and mortality 
in the sub-population defined as fit (adj. HR 0.92 [95% CI 
0.11–7.78]) or pre-frail (adj. HR 1.40 [95% CI 0.66–2.97]). 
Benzodiazepine prescription was associated with a 
decreased risk of mortality in the sub-population defined as 
frail (adj. HR 0.43 [95% CI 0.21–0.86]). The use of tricyclic 
antidepressants was not associated with greater subsequent 
mortality in any of the frailty sub-groups: fit older people 
(data unavailable), pre-frail participants (adj. HR 1.84 [95% 
CI 0.98–3.44]) and frail participants (adj. HR 0.90 [95% 
CI 0.55–1.48]). This was also the case for the ‘other anti-
depressants’ group: fit older people (adj. HR 0.86 [95% CI 
0.23–3.20]), pre-frail (adj. HR 1.12 [95% CI 0.67–1.89] and 
frail (adj. HR 0.74 [95% CI 0.49–1.12]) (Table 3).
3.9.5  Risk of Bias Within Studies
All studies were identified as being at serious risk of bias 
from selection of participants. One study was additionally 
identified as being at further serious risk of bias due to miss-
ing data [45] (Table 4). The main concerns regarding selec-
tion bias included self-selection of participants [38, 39, 47], 
loss to follow-up or gaps in follow-up [35, 41, 43–46] and 
participants not followed from first exposure of anticholin-
ergics [35–47]. Additionally, the characterisation of partici-
pants as frail if they could not complete some clinical assess-
ments potentially introduced case ascertainment bias [44]. 
Finally, bias due to residual confounding was identified as a 
potential issue for all thirteen included studies.
4  Discussion
4.1  Key Findings
This review is the first to the authors’ knowledge to sum-
marise associations between anticholinergic medications 
and key outcomes among frail older populations. This 
review identified that anticholinergic medications are asso-
ciated with reduced ability for chair standing, slower gait 
speeds, increased risk of falls, increased risk of mortality 
and poorer physical performance, among older people liv-
ing with frailty. Conflicting results were reported for the 
effect of anticholinergics on grip strength, TUGT, cogni-
tion and ability to perform ADL. Anticholinergics were 
not shown to be associated with transitions between frailty 
states, psychological wellbeing or ADRs with benzodiaz-
epine use.
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This review identifies that older people living with 
frailty are at greater risk of adverse outcomes when 
exposed to anticholinergic medicines; however, there is 
insufficient evidence to suggest that frailty grade can mod-
ify these risks. The three studies that stratified by frailty 
grade did not clearly demonstrate evidence of a differential 
effect of anticholinergic medications because of frailty sta-
tus [35, 37, 44], and therefore it remains unclear whether 
exposure amongst those with advancing frailty presents 
greater risks than for fit older people.
The difference between fit older adults and those with 
frailty in the association between anticholinergics and 
adverse outcomes did appear to vary among different out-
comes, however. For example, PCS scores appeared to differ 
across the frailty spectrum in those exposed to anticholiner-
gic medicines. Every one-unit increase in the ACB score was 
associated with a doubling in the reduction of the PCS score 
amongst those deemed pre-frail/frail, compared to fit older 
people, representing a greater decrease in physical function. 
However, from a clinical perspective, the effects were small 
and likely not relevant [37]. There is much evidence that 
frailty is graded; however, in this study the pre-frail and frail 
were considered one group in the reporting of results, limit-
ing the inferences that can be made across the frailty spec-
trum. On the other hand, falls as an adverse event appeared 
to be uniform from anticholinergic medicines across the 
frailty spectrum. Although both the frail and the fit admit-
ted to a tertiary hospital setting were at increased risk of 
falls associated with FRID exposure, there was no clinically 
significant difference in risk between people with frailty and 
fit older people [35]. This may suggest that the risk is appar-
ent for older people as a whole, regardless of frailty grade. 
Although the majority of medicines used to characterise the 
FRID exposure variable were of an anticholinergic nature, 
FRIDs were not exclusively anticholinergic, and therefore 
challenges inferences made specifically for anticholinergics 
in this study.
Overall, this review has identified limited evidence with a 
specific focus on associations between anticholinergic medi-
cations and adverse events among older adults with frailty. 
Such associations among older people in general have been 
studied extensively internationally [11–13, 56]; however, few 
observational studies have focused on older people living with 
frailty, and the risks associated with anticholinergic burden in 
this population are therefore not fully understood. This high-
lights a significant gap in the literature in an area becoming 
increasingly important within medicines optimisation.
4.2  Findings in Context of Wider Research 
Literature
This review is consistent with other systematic reviews in 
finding that anticholinergic medications are associated with 
increased risks among older people [11–13, 56]; however, 
unlike this review, those reviews did not have a focus on 
frailty. Additionally, the lack of associations observed within 
some analyses within this review is also consistent with 
other literature, complementing Welsh et al.’s perspectives 
that associations are not as clear as others have suggested, 
and the risks associated with anticholinergic burden are not 
fully understood [11].
Nishtala et al. reported that exposure to DBI drugs in 
older people was associated with falls, subsequently leading 
to hospitalisations [57]. In another study, increasing DBI 
exposure was found to be associated with slower gait speeds 
in 1705 individuals over 70 years old [58], with similar find-
ings to studies in this review [36, 38, 42]. Also consistent 
with this review, there are mixed results for cognition, with 
a 2-year longitudinal study observing associations between 
drugs with anticholinergic activity and cognitive dysfunc-
tion [59]; however, a lack of association with cognitive dys-
function has also been reported within the literature [11]. 
Frailty was not identified within these study populations, 
and therefore the results represent older populations in gen-
eral; however, this systematic review can complement this 
existing literature, highlighting how similar findings can also 
be identified among older adults deemed to be living with 
frailty.
Interestingly, this review identified a study which did not 
observe an association between benzodiazepine use and ‘any 
ADRs’ among older people with frailty [40]. This finding 
is inconsistent with the wider literature as there is general 
acceptance that such medicines can cause adverse effects, 
such as sedation and cognitive decline, particularly among 
older people [60, 61], and that long-acting benzodiazepines 
are often involved in patients with ADRs [62]. The multivar-
iate model used for the benzodiazepine analyses accounted 
for seventeen potential risk-factors, and it is possible that 
over-adjustment may have occurred, whereby variables on 
the causal pathway from exposure to outcome may have been 
controlled for. This could potentially reduce the precision of 
the results. The use of warfarin was found to be associated 
with ‘any ADRs’ and ‘preventable ADRs’, however. It is 
thought that warfarin may have mild anticholinergic activity 
[53]; however, its association with increased risk of ADRs 
is more likely to be related to its bleeding risk than antimus-
carinic effects [63]; therefore, this has not been considered a 
significant finding in the context of anticholinergic burden.
Since completion of this review, a new cross-sectional 
study has been published (June 2020) [64], studying 520 
community-dwelling older adults selected from a geriatric 
outpatient clinic in Turkey. Frailty was identified using the 
phenotype model. The use of any drugs with possible or 
definite anticholinergic activity (defined by the ACB scale) 
was associated with an increased risk of falls in frail par-
ticipants (adj. OR 3.84 [95% CI 1.48–9.93], p = 0.006) and 
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pre-frail participants (adj. OR 2.71 [95% CI 1.25–5.89], p = 
0.012), but not in fit older adults. This supports the hypoth-
esis that frailty grade may potentially modify the risks of 
adverse outcomes when exposed, as in this case the risk of 
falls among the frail was significantly greater than in the pre-
frail. However, the study was limited by its cross-sectional 
design, meaning that the total duration of exposure to ACB 
medicines could not be assessed. Furthermore, there were 
concerns over the reliance on self-reported data from par-
ticipants. In addition, the lack of observed association in fit 
participants challenges direct comparisons across the whole 
frailty spectrum, and it remains unclear whether the risks 
amongst those with advancing frailty truly are greater.
4.3  Strengths and Limitations of the Review
This systematic review focuses on older adults with frailty, 
which is an area much understudied. Robustly capturing a 
wide array of anticholinergic exposures, and frailty meas-
ures, with the use of clinical assessments and validated 
frailty screening tools enabled greater capture of relevant 
studies, particularly where anticholinergic burden and frailty 
were not the main focus of the included studies. Methods 
were pre-specified in a published protocol, and following the 
comprehensive search strategy, a fully independent review 
process was maintained throughout, from the initial screen-
ing of titles and abstracts to full-text review, to data extrac-
tion, to the risk of bias assessment, and finally data synthe-
sis. The overall large number of studies included together 
with the robust methodology utilised for selection and data 
analysis can be considered as a strength of this study.
One limitation is that this review is only representative of 
literature up to the search date of 1st August 2019. Although 
forward and backward citation analysis was conducted, it is 
possible that more recently published studies that met the 
inclusion criteria were omitted. A re-run of the comprehen-
sive search was conducted in April 2021 yielding 588 stud-
ies; however, screening of titles, abstracts and full texts was 
not conducted, and it is unclear whether any studies would 
have met the inclusion criteria. The search was limited to 
studies containing phrases relating to ‘frailty’ in the title or 
abstract, and yielded only nine studies, of which two would 
have been eligible for screening of full-texts as per the meth-
ods [64, 65]. However, it is possible more newly published 
studies reported the characteristics of a frail sample, without 
explicitly using phrases such as ‘frailty’ in the texts. There-
fore, a full systematic screening approach is required, as was 
undertaken for the 13 included studies within this review, 
to identify any further studies specifically focusing on frail 
older people.
Only six out of the 13 included studies explicitly reported 
frailty [35, 37, 40, 41, 43, 44], and therefore the full samples 
of the remaining seven included studies were assumed to be 
living with frailty by the review team based on assessment of 
average clinical parameters of frailty measures [36, 38, 39, 
42, 45–47]. This may not have been a true reflection of the 
entire sample, and consequently there may have been older 
participants who were fit. Measurement of frailty was gen-
erally categorised within studies in to fit, pre-frail or frail, 
and thresholds varied; however, it is accepted that frailty is 
graded and exists on a spectrum [24]. There is much debate 
about the thresholds used to characterise frailty, and these 
have not been standardised [66]. Only three studies stratified 
samples by frailty [35, 37, 44], and as the other included 
studies did not stratify, it was not possible to compare asso-
ciations across the frailty spectrum in these studies.
Table 4  Risk of bias assessment using the Risk of Bias in Non-randomized Studies—of Interventions (ROBINS-I) tool
Study Bias due to 
confound-
ing
Selection bias Bias in clas-
sification of 
interventions










Bias in selection 
of the reported 
result
Overall bias
Bennett [35] Moderate Serious Low Low Moderate Low Low Serious
Cao [36] Moderate Serious Low Low Low Low Low Serious
Cossette [37] Moderate Serious Low Low Unclear Low Low Serious
Gnjidic [38] Moderate Serious Low Low Low Low Low Serious
Gnjidic [39] Moderate Serious Moderate Low Low Low Low Serious
Hanlon [40] Moderate Serious Low Low Low Low Low Serious
Jamsen [41] Moderate Serious Low Low Moderate Low Low Serious
Landi [42] Moderate Serious Low Low Unclear Low Moderate Serious
Martinot [43] Moderate Serious Low Low Moderate Low Low Serious
Porter [44] Moderate Serious Low Low Moderate Low Low Serious
Sato [45] Moderate Serious Moderate Low Serious Moderate Moderate Serious
Wilson [46] Moderate Serious Low Low Moderate Low Low Serious
Zia [47] Moderate Serious Moderate Low Low Low Moderate Serious
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With the inclusion criteria allowing for the selection 
of studies with an average sample age of 65 or more, one 
included study had an age range of 58–73 [43], and one 
study selected participants aged 60 and over [41]. Arguably, 
these could represent younger populations, and the outcomes 
reported for younger participants may have impacted on the 
overall outcomes reported for full samples. However, as 
these two studies had overall samples with an average age 
of 65 and over, they were more representative of an older 
population. Therefore, it is unlikely that the inclusion of 
younger participants would have impacted overall results of 
the individual studies, and indeed the overall conclusions of 
this systematic review. It is also possible that a requirement 
of an average age of 65 and over may also have prevented 
the inclusion of studies undertaken in developing countries, 
where older age is considered to commence earlier, such as 
60 or over. However, this did not prevent the inclusion of one 
study from a developing country (Malaysia) [47], in which 
the sample had an average age of 75.3 among those who had 
fallen and 72.1 among the non-fallers.
Anticholinergic measures were heterogeneous, which 
made synthesis of the data challenging, in addition to the 
wide variety of outcomes reported and the diversity of met-
rics used. This highlights the importance of standardising 
these metrics. The DBI, considered as an anticholinergic 
exposure in this review, encompasses an anticholinergic 
component; however, it also includes a sedative component. 
Therefore, this does not exclusively represent anticholiner-
gic medicines; a factor which should be considered when 
interpreting findings in the context of anticholinergics only.
Each study was deemed to be at serious risk of bias, due 
to concerns around selection biases. None of the thirteen 
included studies followed participants from the initiation of 
the exposure, and inevitably a period of follow-up was lost. 
Selection biases also arise if participants volunteer them-
selves for participation, which was a recruitment method 
used by two studies in this review after advertising through 
leaflets, media and word of mouth [39, 47]. In another 
study, control subjects volunteered themselves, whereas 
the cases were enrolled after participating in a separate 
study [47]. Ascertainment bias could also be an issue in 
another study, where participants were categorised as frail 
if data were missing due to the inability to complete clinical 
assessments [44]. Also, five of the thirteen studies included 
cross-sectional analyses, and therefore as the exposure and 
outcome are simultaneously assessed, the temporal relation-
ship between exposure and outcome cannot be ascertained.
It is also possible that inappropriate adjustments may 
have occurred and may have contributed to bias. In the 
study investigating the association between DBI exposure 
and transitions between frailty states and death [41], it 
could be argued that there was a risk of confounding within 
those exposed to DBI medicines, whereby undetermined 
underlying factors could possibly be the cause of both the 
DBI exposure and the frailty progression. The covariates 
identified within this study were adjusted for as confound-
ers, which allowed for the study of associations, but did not 
apply suitable methods to ameliorate bias for causal infer-
ence. It is possible that factors influencing anticholinergic 
exposure are also likely to influence participants’ frailty state 
and may have contributed to bias. Residual confounding that 
remains after adjusting for confounders is another significant 
issue for the included studies.
Finally, where associations between anticholinergic 
exposure and adverse outcomes have been identified in 
frail populations, causal assumptions must also be consid-
ered. Frailty in its own right can also be associated with 
increasing anticholinergic exposure and polypharmacy 
[67]. One must question whether increased anticholinergic 
exposure can contribute to the cause of adverse outcomes, 
such as physical impairment, or whether frailty or multi-
morbidity in their own right have greater contributions, 
which in turn can increase anticholinergic prescribing 
[3]. None of the 13 studies in this review applied rigorous 
causal inference methodology, which therefore limits the 
causal inferences that can be made from the associations 
presented.
4.4  Implications for Clinical Practice and Future 
Research
This review reinforces that frailty status should be an impor-
tant consideration for clinicians when prescribing anticho-
linergic medicines to older people. As evidenced by various 
associations with adverse outcomes, anticholinergic burden 
is a concern in older people living with frailty, and clini-
cians should continue to practice vigilance, including the 
use of deprescribing interventions to ensure prescribing is 
appropriate. Prescribing patterns can differ between frail 
and non-frail older people, particularly as multimorbidity 
in advancing frailty is thought to further drive polypharmacy 
[68, 69]. Additionally, frail older people are more likely to 
be prescribed symptomatic therapies, increasing the poten-
tial for additional anticholinergic medicines to be prescribed 
[68], and therefore anticholinergic burden levels may dif-
fer between the frail and non-frail. Where possible, frailty 
should be identified, and stratified among older patients, to 
assist clinicians with anticholinergic prescribing decisions, 
with a view to limiting associated risks.
This review has also identified mixed results for out-
comes such as grip strength, TUGT and cognitive dysfunc-
tion among older people with frailty; therefore, there is an 
urgent need for further high-quality research to investigate 
the impact of anticholinergic prescribing on older people 
living with this syndrome.
Associations Between Anticholinergics and Adverse Outcomes in Older People with Frailty
Importantly, this review also highlights how it is still 
unclear whether anticholinergic medication exposure is 
associated with greater risk of adverse outcomes for older 
people according to frailty status, and therefore whether 
those with advancing frailty are at greater risk than fit older 
people. Improving knowledge in this area is of importance, 
particularly as older patients are being identified, prioritised 
and proactively targeted for medication reviews, based on 
frailty grade [5]. Those exposed to anticholinergic medicines 
should continue to be identified and prioritised for review. 
However, there remains a knowledge gap surrounding the 
risk modifying potential of frailty grade, with regards to 
adverse outcomes associated with anticholinergic burden. 
Few studies in this area have stratified by frailty grade; 
therefore, future observational research should identify and 
stratify frailty within study populations using robust meth-
ods, as recommended by the European Medicines Agency in 
clinical investigations involving medicines [70].
5  Conclusions
This systematic review of observational studies has identi-
fied that prescribing anticholinergic medications is associ-
ated with poorer physical function, increased risk of falls 
and increased mortality among older adults living with 
frailty. Mixed results were seen for grip strength, TUGT, 
cognitive dysfunction and ability to perform ADL, and no 
associations were observed for transitions in frailty states, 
lower psychological wellbeing or ADRs with benzodiaze-
pine use. It remains uncertain whether those with advancing 
frailty are at a greater risk from anticholinergic medicines 
compared with older people deemed to be fit or whether 
older people are generally at greater risk, regardless of their 
frailty status. There is an urgent need for this issue to be 
further evaluated within studies that robustly minimise bias 
and stratify by frailty.
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